AstraZeneca to explore options for future of its Covid-19 vaccine

'Is the vaccine businesses a sustainable business for AstraZeneca for the next five or 10 years, that big strategic question is under discussion'

AstraZeneca has been touted as a major weapon against the pandemic because it is cheaper and easier to use than some rivals. File picture

AstraZeneca is exploring its options for the future of its Covid-19 vaccine business and expects greater clarity on the matter by the end of 2021, a senior executive has said. 

"We are exploring different options," Ruud Dobber, executive vice president and president of the BioPharmaceuticals Business Unit, said, referring to the vaccines business.